RAND Corporation Senior Health Policy Researcher Andrew Mulcahy says the U.S. should find its own solutions for tackling high drug prices and pricing transparency.
While referencing drug pricing in other countries can bring about short-term solutions to the problem, Mulcahy writes in an article published on The Hill, it would ultimately “amount to the U.S. free-riding on the work of the UK NICE and other organizations.”
“Ultimately, the U.S. could be better off developing its own capabilities to attack the issue of drug prices transparently on a national scale,” he writes. “While this could seem a long way off, so did serious proposals to weave drug prices from other countries into U.S. policies only a year ago.”
To read the full article, click here.